Literature DB >> 17227820

CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs.

Reginald C Gray1, John Kuchtey, Clifford V Harding.   

Abstract

Deoxycytidyl-deoxyguanosine [(CpG)3] oligodeoxynucleotides (ODNs) signal through TLR9 to induce type-I IFN (IFN-alphabeta) and IFN-alphabeta-dependent MHC-I cross-presentation of exogenous antigens by dendritic cells (DCs). A puzzle was presented by our observation that three ODN classes, CpG-A, CpG-B, and CpG-C, had similar efficacy for induction of IFN-alphabeta-dependent MHC-I antigen cross-presentation by myeloid DCs despite greatly differing for induction of IFN-alphabeta (CpG-A>CpG-C>>CpG-B). All ODN classes similarly enhanced plasmacytoid DC (pDC) presentation of exogenous MHC-I-restricted peptide, although pDCs did not cross-process protein antigen. MHC-I and the transporter for antigen presentation were induced by all ODN classes or IFN-alpha. CpG-B ODNs were slightly more potent than CpG-A or CpG-C ODNs for induction of low levels of IFN-alphabeta but less efficacious at high concentrations than CpG-A or CpG-C ODNs. Low levels of IFN-alphabeta induced by CpG-B ODNs sufficed for full induction of MHC-I cross-presentation. Thus, CpG-B ODNs are slightly more potent but less efficacious than CpG-A and CpG-C ODNs for induction of IFN-alphabeta. High sensitivity to IFN-alphabeta allows CpG-B ODNs to be equally efficacious for induction of MHC-I cross-presentation. CpG-B ODNs may be effective for inducing therapeutic responses that require low levels of IFN-alphabeta and may avoid unnecessarily high induction of IFN-alphabeta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227820     DOI: 10.1189/jlb.1006606

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  21 in total

1.  Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation.

Authors:  Juliette Mouriès; Gabriel Moron; Géraldine Schlecht; Nicolas Escriou; Gilles Dadaglio; Claude Leclerc
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

2.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.

Authors:  Wei Jiang; Michael M Lederman; Clifford V Harding; Scott F Sieg
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

Review 4.  Plasmacytoid dendritic cells in HIV infection: striking a delicate balance.

Authors:  Patricia Fitzgerald-Bocarsly; Evan S Jacobs
Journal:  J Leukoc Biol       Date:  2010-02-09       Impact factor: 4.962

5.  Toll-like receptors are potential therapeutic targets in rheumatoid arthritis.

Authors:  Siamak Sandoghchian Shotorbani; Zhao-Liang Su; Hua-Xi Xu
Journal:  World J Biol Chem       Date:  2011-07-26

6.  CpG-B oligodeoxynucleotides inhibit TLR-dependent and -independent induction of type I IFN in dendritic cells.

Authors:  Yi C Liu; Reginald C Gray; Gareth A D Hardy; John Kuchtey; Derek W Abbott; Steven N Emancipator; Clifford V Harding
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

7.  Distinct responses of splenic dendritic cell subsets to infection with Listeria monocytogenes: maturation phenotype, level of infection, and T cell priming capacity ex vivo.

Authors:  L M Mitchell; K L Brzoza-Lewis; C J Henry; J M Grayson; M M Westcott; E M Hiltbold
Journal:  Cell Immunol       Date:  2011-03-11       Impact factor: 4.868

8.  Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.

Authors:  Bethany D Harris; Jessica Schreiter; Marc Chevrier; Jarrat L Jordan; Mark R Walter
Journal:  J Biol Chem       Date:  2018-08-31       Impact factor: 5.157

9.  Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.

Authors:  Daimon P Simmons; David H Canaday; Yi Liu; Qing Li; Alex Huang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2010-07-21       Impact factor: 5.422

10.  Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production.

Authors:  Chang-Qing Xia; Ruihua Peng; Anna V Chernatynskaya; Lihui Yuan; Carolyn Carter; John Valentine; Eric Sobel; Mark A Atkinson; Michael J Clare-Salzler
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.